Esmo 2020 – Mersana holds steady in ovarian cancer
Expectations grow with more data on XMT-1536, but durability is still a key question.
Esmo 2020 preview – a kidney cancer showdown gets star billing
Though late-breakers rightfully seize much of the limelight at the Esmo congress, investors should look further afield too.
Asco 2019 event analyser – low-key meeting belies some huge stock moves
Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.
Corporate venture firms – dedicated followers of fashion?
Eagerly pursuing all the latest fads and trends.
